NTLA-2001
Intellia Therapeutics
[]
will crispt-based in vivo genome editing in humans be the next therapeutic generation for ttr amyloidosis? amazing data from dr. julian gillmore, ntla-2001
#aha22 
Cardiology resident, Cardiac imaging & Heart failure, University Heart Center Dresden, European society of cardiology & American heart association member??